Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Financials ($)
Sales 2017 90,4 M
EBIT 2017 13,0 M
Net income 2017 -0,14 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 130 M
EBIT 2018 28,2 M
Net income 2018 13,0 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 40,33
EV / Sales2017 5,90x
EV / Sales2018 4,09x
Capitalization 461 M
More Financials
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
07/27Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
10:12p TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Submission of Matters to a Vote of S..
10:11p TELIGENT, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/16 TELIGENT, INC. : To Present At Bank Of America Merrill Lynch Healthcare Conferen..
05/10 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Results of Operations and Financial ..
05/10 TELIGENT : Results of Operations and Financial Condition, Financial Statements a..
05/10 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
05/03 TELIGENT, INC. : To Present At Deutsche Bank 42nd Annual Health Care Conference ..
05/03 TELIGENT : tops 1Q profit forecasts
05/02 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
05/02 TELIGENT, INC. : Announces First Quarter 2017 Results
More news
Sector news : Pharmaceuticals - NEC
07:35p JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
06:10p FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
MERCK & CO., INC.9.65%175 160
More Results